Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by ...

Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Should You Avoid Pfizer? Here's the Key Risk to Watch

Pfizer has reached a turning point.
BioPharma Dive

Pfizer’s Ibrance successor moves forward with new study data

The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement upon Ibrance and other, similar breast cancer medicines from Eli Lilly and ...
Fierce Biotech

Pfizer adds to Seagen scrap heap with another early cancer candidate cull

About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...
BioPharma Dive

Pfizer aims for wider use of PARP drug in prostate cancer with new data

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...